Crinetics Pharmaceuticals Inc (CRNX)

Over the past six months, the FDA approved PALSONIFY in September 2025, leading to a U.S. commercial launch in Q4 2025, generating $5.4 million in net product revenue, and $10.3 million in Q1 2026. Crinetics reported its Q4 2025 financial results on February 26, 2026, after which CRNX shares declined by 6.0%. On May 7, 2026, Crinetics reported Q1 2026 revenue of $10.7 million, exceeding forecasts, and an EPS of -$1.23, surpassing expectations, causing the stock to rise 4.27% in after-hours trading. In March 2026, Crinetics submitted a Marketing Authorization Application for PALSONIFY in Brazil, and the European Commission approved PALSONIFY for acromegaly in adults. Between April 7, 2025, and April 2, 2026, the share price increased by 41.13%. As of May 8, 2026, the stock price was $37.48, representing a 22.16% increase over the past year. In March 2026, the CEO and CFO sold shares at average prices of $37.37 and $39.67, respectively.

There is no explicit information available indicating significant demand seasonality for Crinetics Pharmaceuticals, Inc.'s products and services. The demand for its therapeutics is likely driven by disease prevalence and treatment needs rather than seasonal fluctuations.

Crinetics Pharmaceuticals, Inc. is a global pharmaceutical company focused on discovering, developing, and commercializing novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's pipeline includes PALSONIFY™ (Paltusotine), an oral somatostatin receptor type 2 (SST2) agonist approved for acromegaly and in Phase 3 development for carcinoid syndrome; Atumelnant (CRN04894), an investigational oral ACTH antagonist in Phase 2 studies for CAH and Cushing's disease; CRN09682, a nonpeptide drug conjugate candidate for SST2-expressing neuroendocrine tumors; and other programs addressing endocrine conditions.

Crinetics Pharmaceuticals, Inc. is headquartered in San Diego, California, and has a global pharmaceutical focus. In 2024, it established its first office outside the U.S. in Zug, Switzerland. The company is expanding internationally, with a Marketing Authorization Application for PALSONIFY submitted to Brazil's ANVISA in March 2026 and an agreement with Sanwa Kagaku Kenkyusho Co., Ltd to develop and commercialize Paltusotine in Japan.

Crinetics Pharmaceuticals' brand reputation has been significantly bolstered by the FDA approval of PALSONIFY and its successful U.S. commercial launch. Analysts have given Crinetics a consensus rating of "Moderate Buy" with an average 12-month price target of $76.63. While the company has shown revenue growth, it remains unprofitable, and losses have increased over the past five years. Zacks Investment Research currently rates Crinetics Pharmaceuticals, Inc. as a "Hold." The European Commission's approval of PALSONIFY has also drawn interest from high-profile investors and hedge funds.

Crinetics Pharmaceuticals, Inc. is primarily owned by institutional shareholders, who hold approximately 91.6% to 106.59% of the stock. Major institutional owners include Fmr LLC, Vanguard Group Inc, Wellington Management Group LLP, and BlackRock, Inc. Individual insiders own about 1.31% to 12.42% of the company's stock. Perceptive Advisors LLC is noted as a large individual shareholder, owning 7.55% of the company.